Effects of statins on survival outcomes in patients with metastatic renal cell carcinoma
10.12173/j.issn.2097-4922.202406053
- VernacularTitle:他汀类药物对转移性肾细胞癌生存结局的影响
- Author:
Shiliang GAO
1
;
Xiaoqi HE
;
Huijie ZHENG
;
Di YANG
;
Mingzhu YU
Author Information
1. 联勤保障部队第九○八医院泌尿外科(南昌 330000)
- Keywords:
Metastatic renal cell carcinoma;
Statins;
Survival outcomes;
Overall survival;
Progression-free survival;
Objective response rate;
Disease control rate
- From:
China Pharmacist
2024;28(9):28-33
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the impact of statins combined with sorafenib(SRF)therapy on survival outcomes in patients with metastatic renal cell carcinoma(mRCC).Methods Clinical data of mRCC patients treated in the 908th Hospital of the Joint Security Force from November 2019 to November 2023 were retrospectively analyzed.They were categorized into statin group and non-statin group according to whether they used statins or not,and the differences in the primary endpoint of overall survival(OS),secondary endpoints of progression-free survival(PFS),objective response rate(ORR),and disease control rate(DCR)were compared between the two groups.Results A total of 80 patients were included in the study,with 27 in the statin group and 53 in the non-statin group.There were no statistically significant differences in partial remission,stable disease,disease progression,and DCR between the two groups(P＞0.05);complete remission and ORR were significantly higher in the statin group than in the non-statin group(P＜0.05).Kaplan-Meier analysis showed that,compared with the non-statin group,the median PFS and OS of the statin group were prolonged,and the difference in median PFS between the two groups was statistically significant(P＜0.05).In terms of safety,the incidence of other adverse events was similar in both groups(P＞0.05).Conclusion Statins combined with SRF treatment regimen can improve ORR and DCR and prolong median PFS and OS in patients with mRCC.
